» Articles » PMID: 37733169

Diverse Functions of Myeloid-derived Suppressor Cells in Autoimmune Diseases

Overview
Journal Immunol Res
Date 2023 Sep 21
PMID 37733169
Authors
Affiliations
Soon will be listed here.
Abstract

Since myeloid-derived suppressor cells (MDSCs) were found suppressing immune responses in cancer and other pathological conditions, subsequent researchers have pinned their hopes on the suppressive function against immune damage in autoimmune diseases. However, recent studies have found key distinctions of MDSC immune effects in cancer and autoimmunity. These include not only suppression and immune tolerance, but MDSCs also possess pro-inflammatory effects and exacerbate immune disorders during autoimmunity, while promoting T cell proliferation, inducing Th17 cell differentiation, releasing pro-inflammatory cytokines, and causing direct tissue damage. Additionally, MDSCs could interact with surrounding cells to directly cause tissue damage or repair, sometimes even as an inflammatory indicator in line with disease severity. These diverse manifestations could be partially attributed to the heterogeneity of MDSCs, but not all. The different disease types, disease states, and cytokine profiles alter the diverse phenotypes and functions of MDSCs, thus leading to the impairment or obversion of MDSC suppression. In this review, we summarize the functions of MDSCs in several autoimmune diseases and attempt to elucidate the mechanisms behind their actions.

Citing Articles

Myeloid derived suppressor cells mediate hepatocyte proliferation and immune suppression during liver regeneration following resection.

Nachmany I, Nevo S, Edelheit S, Sarusi-Portuguez A, Friedlander G, Salame T Genes Immun. 2024; 25(6):483-491.

PMID: 39488626 DOI: 10.1038/s41435-024-00303-5.


Dual roles of myeloid-derived suppressor cells in various diseases: a review.

Nepal M, Shah S, Kang K Arch Pharm Res. 2024; 47(7):597-616.

PMID: 39008186 DOI: 10.1007/s12272-024-01504-2.


Exploring the Potential of Glycolytic Modulation in Myeloid-Derived Suppressor Cells for Immunotherapy and Disease Management.

Kim J, Choi J, Min H, Hwang K Immune Netw. 2024; 24(3):e26.

PMID: 38974210 PMC: 11224668. DOI: 10.4110/in.2024.24.e26.


Thrombopoietin receptor agonists regulate myeloid-derived suppressor cell-mediated immunomodulatory effects in ITP.

Zhu Y, Wang Y, Zhao Y, Liu D, Wang X, Zhu L Ann Hematol. 2024; 103(8):2729-2741.

PMID: 38890176 DOI: 10.1007/s00277-024-05846-1.

References
1.
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

2.
Sagiv J, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L . Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015; 10(4):562-73. DOI: 10.1016/j.celrep.2014.12.039. View

3.
Dorhoi A, Kotze L, Berzofsky J, Sui Y, Gabrilovich D, Garg A . Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. J Clin Invest. 2020; 130(6):2789-2799. PMC: 7260010. DOI: 10.1172/JCI136288. View

4.
Zhang H, Wang S, Huang Y, Wang H, Zhao J, Gaskin F . Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin Immunol. 2015; 157(2):175-86. PMC: 4657752. DOI: 10.1016/j.clim.2015.02.001. View

5.
Yin B, Ma G, Yen C, Zhou Z, Wang G, Divino C . Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol. 2010; 185(10):5828-34. PMC: 4355963. DOI: 10.4049/jimmunol.0903636. View